Shilpa Medicare Ltd

Shilpa Medicare Ltd recorded a robust intraday performance on 09 Feb 2026, surging to a day’s high of Rs 359.95, marking a significant 7.33% gain. The pharmaceutical and biotechnology company outpaced its sector and the broader market, reflecting heightened trading activity and volatility.

Shilpa Medicare Ltd commenced trading today with a significant gap up, opening 14.47% higher than its previous close, signalling robust positive sentiment in the Pharmaceuticals & Biotechnology sector. This strong start was accompanied by heightened volatility and outperformance relative to both its sector and the broader market indices.

Shilpa Medicare Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, shifting its financial trend from positive to very positive. The pharmaceutical and biotechnology company recorded its highest quarterly net sales and profitability metrics in recent history, signalling a potential turnaround despite a challenging broader market environment.

Shilpa Medicare Ltd., a Raichur-based pharmaceutical company specialising in active pharmaceutical ingredients (APIs), formulations, and contract development, reported consolidated net profit of ₹44.58 crores for Q3 FY26 (October-December 2025), marking a marginal 1.16% quarter-on-quarter increase but a robust 40.28% year-on-year surge. Despite the impressive earnings growth, the stock has languished, trading at ₹318.00 with a market capitalisation of ₹6,122 crores, down 36.60% from its 52-week high of ₹501.60.

Shilpa Medicare Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 5 February 2026. This change reflects nuanced shifts across four critical parameters: quality, valuation, financial trend, and technicals. Despite persistent challenges in long-term fundamentals, recent technical improvements and valuation metrics have prompted a more favourable outlook, albeit still cautious.

Shilpa Medicare Ltd has exhibited a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook, reflecting nuanced changes in key indicators such as MACD, RSI, and moving averages. Despite a modest daily gain of 1.12%, the pharmaceutical company’s technical profile remains cautious, with mixed signals across weekly and monthly timeframes suggesting a complex near-term trajectory.

Shilpa Medicare Ltd commenced trading on 3 Feb 2026 with a notable gap up, opening 7.94% higher than its previous close, signalling a strong start driven by positive market momentum within the Pharmaceuticals & Biotechnology sector.

Shilpa Medicare Ltd recorded a robust intraday performance on 1 Feb 2026, surging to a day’s high of Rs 313.5, marking an 8.1% increase and closing with a notable 7.95% gain. This surge outpaced the Pharmaceuticals & Biotechnology sector by 7.1%, reflecting heightened trading activity and volatility in the stock.

Shilpa Medicare Ltd recorded a robust intraday performance on 30 Jan 2026, surging 8.06% to touch a day’s high of Rs 294.25. This significant uptick outpaced the broader Sensex, which declined by 0.37% during the same session, highlighting the stock’s notable resilience amid a generally subdued market environment.

Shilpa Medicare Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.261.6 today, marking a significant milestone in its ongoing decline. The stock has been on a downward trajectory for 12 consecutive trading sessions, resulting in a cumulative loss of 17.35% over this period.